Gene · 8019
Papers2,104
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
381 to 400 of 2,104
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies. | Cancers (Basel) | 2022 | 36358891 | PubTator, text mining | PubMed |
| The E3 Ligases in Cervical Cancer and Endometrial Cancer. | Cancers (Basel) | 2022 | 36358773 | PubTator, text mining | PubMed |
| Deubiquitinase USP35 stabilizes BRPF1 to activate mevalonate (MVA) metabolism during prostate tumorigenesis. | Cell Death Discov | 2022 | 36357379 | PubTator, text mining | PubMed |
| Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery. | Pharmaceuticals (Basel) | 2022 | 36355538 | PubTator, text mining | PubMed |
| Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes. | BMC Cancer | 2022 | 36348317 | PubTator, text mining | PubMed |
| Epigenetic-Mediated Regulation of Gene Expression for Biological Control and Cancer: Cell and Tissue Structure, Function, and Phenotype. | Results Probl Cell Differ | 2022 | 36348114 | PubTator, text mining | PubMed |
| Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression. | Proc Natl Acad Sci U S A | 2022 | 36343244 | PubTator, text mining | PubMed |
| A synthetic KLHL20 ligand to validate CUL3KLHL20 as a potent E3 ligase for targeted protein degradation. | Genes Dev | 2022 | 36328355 | PubTator, text mining | PubMed |
| A Versatile and Sustainable Multicomponent Platform for the Synthesis of Protein Degraders: Proof-of-Concept Application to BRD4-Degrading PROTACs. | J Med Chem | 2022 | 36323630 | PubTator, text mining | PubMed |
| Functional networks of the human bromodomain-containing proteins. | Front Bioinform | 2022 | 36304339 | PubTator, text mining | PubMed |
| Viral Hijacking of BET Proteins. | Viruses | 2022 | 36298829 | PubTator, text mining | PubMed |
| The Light Chain Domain and Especially the C-Terminus of Receptor-Binding Domain of the Botulinum Neurotoxin (BoNT) Are the Hotspots for Amino Acid Variability and Toxin Type Diversity. | Genes (Basel) | 2022 | 36292800 | PubTator, text mining | PubMed |
| Diagnosis, Treatment and Prognosis of Primary Pulmonary NUT Carcinoma: A Literature Review. | Curr Oncol | 2022 | 36290813 | PubTator, text mining | PubMed |
| Activity of a Novel Anti-Inflammatory Agent F-3,6'-dithiopomalidomide as a Treatment for Traumatic Brain Injury. | Biomedicines | 2022 | 36289711 | PubTator, text mining | PubMed |
| Pharmacophore-Model-Based Virtual-Screening Approaches Identified Novel Natural Molecular Candidates for Treating Human Neuroblastoma. | Curr Issues Mol Biol | 2022 | 36286044 | PubTator, text mining | PubMed |
| Applications of covalent chemistry in targeted protein degradation. | Chem Soc Rev | 2022 | 36285735 | PubTator, text mining | PubMed |
| Identification of bromodomain-containing proteins prognostic value and expression significance based on a genomic landscape analysis of ovarian serous cystadenocarcinoma. | Front Oncol | 2022 | 36276071 | PubTator, text mining | PubMed |
| Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer. | Nat Commun | 2022 | 36274096 | PubTator, text mining | PubMed |
| Nanomaterial-assisted CRISPR gene-engineering - A hallmark for triple-negative breast cancer therapeutics advancement. | Mater Today Bio | 2022 | 36267139 | PubTator, text mining | PubMed |
| Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader. | ACS Med Chem Lett | 2022 | 36262390 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8019/papers?page=20